articleNature MedicineJun 3, 2024HYBRID OA

Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

FMFranck MorschhauserSDSaurabh DahiyaMLM. Lia PalombaAMAlejandro Martı́nJLJuan Luis Reguera Ortega

Centre Hospitalier Universitaire de Lille · University of Maryland, Baltimore · +36 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and high-risk disease features, such as progression of disease within 24 months (POD24) from first-line immunochemotherapy or disease refractory to both CD20-targeting agent and alkylator (double refractory), due to no established standard of care and poor outcomes. Chimeric antigen receptor (CAR) T cell therapy is an option in R/R FL after two or more lines of prior systemic therapy, but there is no consensus on its optimal timing in the disease course of FL, and there are no data in second-line (2L) treatment of patients with high-risk features. Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, 4-1BB…

Citation impact

124
total citations
FWCI
31.24
Percentile
100%
References
32
Citations per year

Authors

33

Topics & keywords

Topics
Keywords
  • Medicine
  • Follicular lymphoma
  • Refractory (planetary science)
  • Internal medicine
  • Follicular phase
  • Lymphoma
  • Oncology
  • Confidence interval
No related works found for this paper.

Funding